OppenheimerFunds Inc. owned about 1.22% of Zimmer Biomet Holdings worth $298,560,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 84.17% of the company's stock. State Street Corp now owns 8,193,165 shares of the medical equipment provider's stock valued at $1,000,463,000 after buying an additional 191,747 shares in the last quarter. Vanguard Group Inc. raised its position in Zimmer Biomet Holdings by 3.7% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider's stock worth $2,044,168,000 after buying an additional 16,336,262 shares during the last quarter. Glenview Capital Management LLC bought a new position in shares of Zimmer Biomet Holdings during the first quarter worth $94,197,000. The legal version of this story can be accessed at https://sportsperspectives.com/2017/07/16/oppenheimerfunds-inc-lowers-position-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html. Dimensional Fund Advisors LP now owns 644,254 shares of the medical equipment provider's stock worth $66,492,000 after buying an additional 80,323 shares during the period. Finally, CENTRAL TRUST Co increased its position in Zimmer Biomet Holdings by 13.0% in the first quarter. The medical equipment provider reported $2.13 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.02.
07/12/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Wells Fargo.
Shares of Zimmer Biomet Holdings (NYSE:ZBH) opened at 132.49 on Friday. The firm has a market cap of $26.72 billion, a P/E ratio of 54.23 and a beta of 1.21. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.21. The company has a 50-day moving average of $123.43 and a 200 day moving average of $117.75.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 EPS for the quarter, topping the Zacks' consensus estimate of $2.11 by $0.02.
06/07/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Citigroup. Janus Capital Management LLC now owns 1,177,645 shares of the medical equipment provider's stock worth $121,533,000 after buying an additional 719,345 shares in the last quarter. Zimmer Biomet Holdings's quarterly revenue was up 3.8% compared to the same quarter previous year. Zimmer Biomet Holdings had 44 analyst reports since August 27, 2015 according to SRatingsIntel.
US provides visas to up to 15000 temporary workers
The Department of Homeland Security (DHS) said this is aimed mainly at better tracking visa overstays and also at tightening security.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 28th. The Schafer Cullen Capital Management Inc holds 973,269 shares with $119.15M value, down from 1.09M last quarter. This represents a $0.96 annualized dividend and a yield of 0.72%. The ex-dividend date is set for Wednesday the 21st of June 2017. Zimmer Biomet Holdings's payout ratio is presently 39.67%. If you are accessing this report on another domain, it was illegally stolen and republished in violation of global copyright legislation. Cantor Fitzgerald added the stock to its research portfolio giving it an initial rating of "Neutral".
07/12/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Needham & Company.
On December 15 the stock rating was downgraded to "Sell" from " by analysts at UBS. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $116.47, for a total transaction of $10,171,441.57. The sale was disclosed in a filing with the SEC, which is available through this link.
In related news, insider David C. Dvorak sold 87,331 shares of the stock in a transaction on Thursday, April 27th. (NYSE:ZBH) shares typically trade an average volume of 1423.96 and institutions hold 86.80% of the total shares. The disclosure for this sale can be found here.
Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce.